Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin

Double-blind, placebo-controlled cosmetic clinical trial conducted by Procter & Gamble researchers with the goal of quantifying the clinical effect of palmitoyl-KTTKS (pal-KTTKS / Matrixyl) on signs of facial photoaging in women. It is the most cited clinical study supporting Matrixyl's efficacy claims in anti-aging cosmetics.

The design was a split-face study in 93 women aged 35 to 55 years, with moderate signs of facial photoaging. Each participant applied twice daily on randomized hemifaces: moisturizer containing 3 ppm of pal-KTTKS versus identical vehicle moisturizer (placebo), for 12 weeks. Outcomes included profilometric analysis of silicone replicas (wrinkles/depth/roughness), blinded expert assessment, and participant self-assessment.

Results showed statistically significant reduction in wrinkle depth, fine-line length and skin roughness on the Matrixyl-treated side versus vehicle, detectable from 4 weeks and progressive through 12 weeks. Participants also reported subjective improvement in fine lines and wrinkles. The product was well tolerated, without significant irritation or cutaneous adverse events.

Despite methodological limitations (single-center study, possible carryover between hemifaces, P&G sponsorship), this work established Matrixyl as one of the few cosmetic peptides with peer-reviewed clinical evidence of anti-wrinkle efficacy in humans. Combined with the foundational work of Katayama 1993 on the molecular mechanism of KTTKS, the Robinson 2005 study forms the backbone of scientific literature supporting Matrixyl use in anti-aging products. It remains an obligatory reference in any review on peptides in dermocosmetics.